Dublin, Sept. 29, 2016 -- Research and Markets has announced the addition of the "Global Point-of-Care Coagulation Testing Market 2016-2020" report to their offering.
The global point-of-care coagulation testing market to grow at a CAGR of 6.53% during the period 2016-2020.
Global Point-Of-Care Coagulation Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. A 360-degree view of the market, based on products, application, and technology segments.
Coagulation testing measures the ability of blood to form a clot. Clotting is the process of the blood converting from a liquid into a gel form. Coagulation tests are carried out to detect clotting disorders such as hemorrhage and thrombosis. Many types of coagulation tests exist, including complete blood count, factor V assay, fibrinogen level, PT, platelet count, TT, and bleeding time.
According to the report, advances in technology will be a key driver for market growth. Vendors are continually investing in R&D to develop products with advanced technology. POCT technology too has evolved from traditional laboratories in terms of quality of tests offered and cost-effectiveness. For instance, the molecular diagnosis is a complex form of testing, and the development of POCT devices for molecular diagnostics is on the rise. In addition, sensor technologies in the medical field have made the rapid analysis of blood samples possible for many critical care assays, including electrolytes, blood gases, and hematology. Biosensors are today being used for toxicology and drug screenings, measurement of blood cells, coagulation disorders, and checking for vitamin K deficiency.
Further, the report states that high cost of coagulation analyzers will be a challenge for the market. POC tests are usually associated with high cost, both in terms of consumables used and TAT. It is difficult to determine the cost-effectiveness of POCT because the cost factor cannot be calculated on the basis of spending on the tests alone. Down savings such as decreased LOS, readmission rates, and improvements in patient outcomes are major factors that fall within the purview of the cost-effectiveness of a test.
Key vendors
- Abbott Laboratories
- Alere Inc.
- F. Hoffmann-La Roche AG
- Siemens AG
Other prominent vendors
- Accriva Diagnostics
- CoaquSense
- Diagon
- Helena Point of Care
- HemoSonics
- iLine Microsystems
- Medtronic
- Micropoint Bioscience
- Sysmex
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Market landscape
Part 06: Segmentation by product
Part 07: Market segmentation by application
Part 08: Market segmentation by technology
Part 09: Market segmentation by end-user
Part 10: Geographical segmentation
Part 11: Market drivers
Part 12: Impact of drivers
Part 13: Market challenges
Part 14: Impact of drivers and challenges
Part 15: Market trends
Part 16: Vendor landscape
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/7r9h2s/global
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Point-of-Care Diagnostics, Coagulation and Hemostasis Testing


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



